On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Matthew Snape is a paediatrician who joined Moderna in 2022 to lead their Paediatric and Maternal Clinical Development team.
Prior to this he worked as the NIHR Oxford BRC Consultant in Vaccinology and Pediatrics at the Oxford Vaccine Group (University of Oxford) and the Oxford Children’s Hospital.
Research interests while at the Oxford Vaccine Group included leading phase 1 to 4 studies on vaccines against pathogens such as RSV, Ebola virus, Influenza, Pneumococcus and Meningococcus. From 2017 to 2022 he led the NIHR funded National Immunisation Schedule Evaluation Consortium (NISEC), tasked with conducting research studies of relevance to UK immunisation policy. In this role he lead the ‘COM-COV’ trials studying heterologous COVID-19 vaccine schedules
Matthew Snape is originally from Melbourne, Australia, where he trained in Paediatrics at the Royal Children’s Hospital.
